The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia.
- Author:
Hidekazu SUZUKI
1
Author Information
- Publication Type:Review
- Keywords: Belching; Dyspepsia; Globus; Heartburn; Nausea
- MeSH: Asia*; Burns; Dyspepsia; Eating; Endoscopy, Digestive System; Eosinophilic Esophagitis; Eructation; Gastroesophageal Reflux; Heartburn; Helicobacter pylori; Meals; Motor Disorders; Muscle Spasticity; Nausea; Prevalence; Satiation; Sensation; Sensitivity and Specificity; Stomach Neoplasms
- From:Journal of Neurogastroenterology and Motility 2017;23(3):325-333
- CountryRepublic of Korea
- Language:English
- Abstract: The Rome criteria were amended as Rome IV. For functional esophageal disorders, the exclusion criteria have been more specifically revised based on further understanding of other esophageal disorders, including eosinophilic esophagitis and spastic and hypercontractile motor disorders. Another revised point is the more restrictive definition of gastroesophageal reflux disease, indicating that sensitivity to a physiological reflux burden may be placed more firmly within the functional group. For functional dyspepsia (FD), only minor changes were introduced, mainly to improve specificity. Among the major symptoms of FD, not only postprandial fullness, but also epigastric pain, epigastric burning, and early satiation should be “bothersome.” Investigation on the effect of meal ingestion on symptom generation has indicated that not only postprandial fullness and early satiety, but also epigastric pain, epigastric burning sensation and nausea (not vomiting) may increase after meals. Helicobacter pylori infection is considered a possible cause of dyspepsia if successful eradication leads to sustained resolution of symptoms for more than 6 months, and such status can be termed as “H. pylori–associated dyspepsia.” Prompt esophagogastroduodenoscopy and H. pylori testing and treatment would be more beneficial, especially in Asia, which has a high prevalence of gastric cancer. Acotiamide, tandospirone, and rikkunshito are the newly listed as treatment options for FD. For further therapeutic development, clinical studies based on the strict Rome IV criteria should be performed.
